Literature DB >> 22611228

Severe premenstrual syndrome and bipolar disorder: a tragic confusion.

John Studd1.   

Abstract

Bipolar disorder and severe premenstrual syndrome (PMS) have many symptoms in common, but it is important to establish the correct diagnosis between a severe psychiatric disorder and an endocrine disorder appropriately treatable with hormones. The measurement of hormone levels is not helpful in making this distinction, as they are all premenopausal women with normal follicle-stimulating hormone and estradiol levels. The diagnosis of PMS should come from the history relating the occurrence of cyclical mood and behaviour changes with menstruation, the improvement during pregnancy, postnatal depression and the presence of runs of many good days a month and the somatic symptoms of mastalgia, bloating and headaches. Young women with severe PMS do not respond to the antidepressants and mood-stabilizing drugs typically used for bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22611228     DOI: 10.1258/mi.2012.012018

Source DB:  PubMed          Journal:  Menopause Int        ISSN: 1754-0453


  3 in total

1.  Association of testosterone levels and future suicide attempts in females with bipolar disorder.

Authors:  Leo Sher; Michael F Grunebaum; Gregory M Sullivan; Ainsley K Burke; Thomas B Cooper; J John Mann; Maria A Oquendo
Journal:  J Affect Disord       Date:  2014-05-05       Impact factor: 4.839

2.  Dysmenorrhea and depressive symptoms among female university students: a descriptive study from Saudi Arabia.

Authors:  Deemah Alateeq; Lolwah Binsuwaidan; Leenah Alazwari; Maram Algarni; Maryam Al Hussain; Raghad Alzahrani; Reema Aljohani
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2022-09-06

3.  Women's experiences of receiving a diagnosis of premenstrual dysphoric disorder: a qualitative investigation.

Authors:  Elizabeth Osborn; Anja Wittkowski; Joanna Brooks; Paula E Briggs; P M Shaughn O'Brien
Journal:  BMC Womens Health       Date:  2020-10-28       Impact factor: 2.809

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.